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ABSTRACT 
VEGF-C2 and VEGF-D are secreted 
glycoproteins that induce angiogenesis and 
lymphangiogenesis in cancer, thereby promoting 
tumor growth and spread.  They exhibit structural 
homology and activate VEGFR-2 and VEGFR-3, 
receptors on endothelial cells that signal for 
growth of blood vessels and lymphatics.  VEGF-C 
and VEGF-D were thought to exhibit similar 
bioactivities, yet recent studies indicated distinct 
signalling mechanisms, e.g. tumor-derived VEGF-
C promoted expression of the prostaglandin 
biosynthetic enzyme COX-2 in lymphatics, a 
response thought to facilitate metastasis via the 
lymphatic vasculature, whereas VEGF-D did not.  
Here we explore the basis of the distinct 
bioactivities of VEGF-D using a neutralizing 
antibody, peptide-mapping and mutagenesis to 
demonstrate that the N-terminal α-helix of mature 
VEGF-D (F93 to R108) is critical for binding 
VEGFR-2 and VEGFR-3.  Importantly, the N-
terminal part of this α-helix, from F93 to T98, is 
required for binding VEGFR-3, but not VEGFR-2.  
Surprisingly, the corresponding part of the -helix 
in mature VEGF-C did not influence binding to 
either VEGFR-2 or VEGFR-3, indicating distinct 
determinants of receptor binding by these growth 
factors.  A variant of mature VEGF-D harbouring 
a mutation in the N-terminal -helix, D103A, 
exhibited enhanced potency for activating 
VEGFR-3, was able to promote increased COX-2 
mRNA levels in lymphatic endothelial cells and 
had enhanced capacity to induce lymphatic 
sprouting in vivo.  This mutant may be useful for 
developing protein-based therapeutics to drive 
lymphangiogenesis in clinical settings such as 
lymphedema.  Our studies shed light on the 
VEGF-D structure/function relationship and 
provide a basis for understanding functional 
differences compared to VEGF-C. 
 
INTRODUCTION 
VEGF-C and VEGF-D are secreted 
protein growth factors that induce proliferation and 
sprouting of endothelial cells lining blood vessels 
and lymphatic vessels, and promote angiogenesis 
and lymphangiogenesis in developing tissues and 
pathologies such as cancer (1-4).  They induce 
metastasis in animal models of cancer, exhibit 
expression patterns in a range of human cancers 
that correlate with parameters of tumor 
development, and are considered potential targets 
for therapeutics designed to restrict tumor growth 
and spread (5-17).  VEGF-C and VEGF-D may 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M116.736801The latest version is at 
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also play roles in suppressing the immune 
response to cancer.  For example, tumor-derived 
VEGF-C and associated lymph node 
lymphangiogenesis suppressed anti-tumor 
immunity in a murine melanoma model; this type 
of immunomodulatory effect, involving an 
immunosuppressive function of lymphatic 
endothelial cells (LECs), may be relevant for 
design of future immunotherapeutic strategies for 
cancer (18,19).  In other disease settings, VEGF-C 
and VEGF-D are being explored in approaches to 
drive therapeutic angiogenesis and/or 
lymphangiogenesis for cardiovascular medicine 
and lymphedema (9,20,21).   
Both VEGF-C and VEGF-D are initially 
produced as precursor proteins comprising N- and 
C-terminal propeptides flanking a central VEGF 
homology domain (VHD) containing binding sites 
for VEGFR-2 and VEGFR-3, cell surface 
receptors on endothelial cells that signal for 
angiogenesis and lymphangiogenesis (22-24).  
Proteolytic processing can remove the propeptides 
to generate mature VEGF-C and VEGF-D, which 
activate VEGFR-2 and VEGFR-3 thus driving the 
growth of blood vessels and lymphatics (25-31).   
Broadly, VEGF-C and VEGF-D are 
thought to exhibit similar receptor binding 
specificities and biological activities.  However, 
recent findings suggested there may be differences 
in the structure/function relationships for these two 
growth factors.  For example, it has been reported 
that the choice of the N-terminal processing site 
for production of mature VEGF-D can profoundly 
influence receptor specificity (32), whereas there 
has been no such report for VEGF-C.  Further, 
studies in mouse models of cancer showed that 
VEGF-C produced by tumor cells promoted 
expression of COX-2 (an enzyme involved in the 
biosynthesis of prostaglandins) in the endothelial 
cells of collecting lymphatic vessels, whereas 
VEGF-D did not, indicating that these growth 
factors may exhibit distinct regulatory mechanisms 
for promoting metastasis via the lymphatic 
vasculature (5).  Differences in the functions of 
VEGF-C and VEGF-D are important from the 
perspective of cancer biology given that these 
growth factors can exhibit distinct patterns of 
expression in human tumors (8,33).  For example, 
VEGF-C has been reported to be up-regulated in 
head and neck cancer versus normal epithelium 
whereas VEGF-D expression is down-regulated 
(34); conversely VEGF-D, but not VEGF-C, was 
reported to be an independent predictor of poor 
outcome in epithelial ovarian carcinoma (35). 
The crystal structures of mature human 
VEGF-C bound to portions of VEGFR-2 and 
VEGFR-3 have been reported (36,37), and the 
crystal structure of a variant of mature human 
VEGF-D (VEGF-D C117A) has been determined 
(32).  However, there have been no reports of 
structures for VEGF-D in complex with either 
VEGFR-2 or VEGFR-3, so the structural 
determinants important for the interaction of 
VEGF-D with its receptors remain to be fully 
characterized.  Here we identify amino acid 
residues in the N-terminal α-helix of mature 
VEGF-D that are critical for receptor binding and 
the bioactivities of this protein.  We show that the 
comparable region of VEGF-C is not a key 
determinant of receptor binding, which indicates 
divergent mechanisms for receptor interactions in 
VEGF-C versus VEGF-D.  Our findings have 
potential clinical significance for developing 
monoclonal antibodies to block VEGF-D in 
cancer, and for optimizing protein growth factors 
to promote therapeutic lymphangiogenesis and 
lymphatic remodeling to treat lymphedema and 
inflammatory conditions. 
 
RESULTS 
Mapping the binding site in VEGF-D of an 
antibody that blocks interactions with VEGFR-2 
and VEGFR-3—We previously employed a 
neutralizing monoclonal antibody (mAb) to mature 
human VEGF-D, designated VD1, to identify part 
of the binding site in VEGF-D for VEGFR-2 and 
VEGFR-3.  The region thus identified, 
147NEESL151, was located in the L2 loop on the 
pole of the VEGF-D monomer (38).  In order to 
identify other regions of VEGF-D critical for 
receptor interactions and the distinct biological 
activities of this growth factor, we assessed a panel 
of commercially-available and in-house VEGF-D 
mAbs for neutralizing capacity in bioassays of 
binding and cross-linking of VEGFR-2 and 
VEGFR-3.  These assays employed cell lines 
expressing chimeric receptors consisting of the 
entire extracellular domain of VEGFR-2 or 
VEGFR-3 and the trans-membrane and 
cytoplasmic domains of the mouse erythropoietin 
receptor (25).  Binding and cross-linking of the 
chimeric receptors allows these cells to survive 
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and proliferate in the absence of interleukin-3 (IL-
3).  This analysis demonstrated that the 
commercially-available mAb 286 blocks binding 
and cross-linking of both VEGFR-2 and VEGFR-3 
by a form of mature human VEGF-D previously 
designated VEGF-DNC (22) (Figure 1A).  The 
neutralizing VD1 mAb was included as a positive 
control, which blocked binding and cross-linking 
of both receptors by VEGF-DNC, as reported 
previously (39).  The VD4 mAb, which binds 
VEGF-DNC but does not block the interactions 
of this ligand with VEGFR-2 or VEGFR-3, was 
also included and had no effect on receptor 
binding and cross-linking in the bioassays, as 
expected (39). 
We mapped the binding site of mAb 286 
by ELISA using a synthetic peptide library 
covering the amino acid sequence of VEGF-
DNC (Figure 1B).  Positive signals were 
detected for interactions of mAb 286 with three 
peptides which had the sequence 95DIETLKVID103 
in common.  This sequence is located near the N-
terminus of VEGF-DNC and lies in the N-
terminal -helix of mature VEGF-D (32).  To 
confirm these findings, we generated mutants of 
VEGF-DNC with each residue in the 
95DIETLKVID103 region individually converted to 
alanine.  The interaction of these mutants with 
mAb 286 was monitored by Western blotting and 
ELISA which demonstrated that various residues 
in this region are important for binding this mAb.  
For example, mutation of either D95 or T98 to 
alanine completely abrogated binding to mAb 286 
as assessed by Western blotting (Figure 1C) and 
almost completely abrogated binding in the ELISA 
(Figure 1D).  Mutation of E97, L99, K100 or D103 
to alanine reduced binding to mAb 286 as assessed 
by both methods, but not to the same degree as 
D95 or T98.  These findings confirm the 
importance of the 95DIETLKVID103 region in the 
N-terminal -helix of mature VEGF-D for the 
interaction with mAb 286.  Our results also show 
that targeting this region of mature VEGF-D with 
a mAb can prevent this growth factor from binding 
and cross-linking VEGFR-2 and VEGFR-3. 
Identification of residues in the N-terminal 
α-helix critical for receptor activation—The data 
presented above indicate that mAb 286 blocks the 
interactions of VEGF-D with VEGFR-2 and 
VEGFR-3 by binding to the N-terminal -helix of 
mature VEGF-D.  However, it was not known if 
this mAb binds the same or overlapping sites on 
VEGF-D as these receptors, or if binding occurs at 
distinct sites and the neutralizing effect of the mAb 
is due to steric hindrance.  To explore the 
importance of specific amino acid residues in the 
N-terminal α-helix of mature human VEGF-D for 
receptor binding and activation, we studied VEGF-
D mutants in which each residue from position 93 
to 108 had been individually altered to alanine (see 
Figure 2A for locations of these residues).  We 
tested binding of VEGF-DΔNΔC variants to both 
VEGFR-2 and VEGFR-3 in receptor-binding 
ELISAs and in bioassays of receptor binding and 
cross-linking.  These data showed that alteration to 
alanine of each of the residues from F93 to T98, 
i.e. the first six residues of the structure shown in 
Figure 2A, had no effect on the interaction with 
VEGFR-2 (Figure 2B and C, left panels), while for 
VEGFR-3, alteration of Y94 to alanine led to a 
dramatic decrease of receptor binding and cross-
linking (Figure 2B and C, right panels).  Similar 
loss of VEGFR-3 binding and cross-linking was 
seen with the L99A mutant, and this mutant also 
exhibited decreased binding and cross-linking of 
VEGFR-2.  Likewise, alteration of residues C-
terminal to L99, that reduced VEGFR-3 binding 
and cross-liking (e.g. I102A, E105A and W106A), 
also reduced binding and cross-linking of VEGFR-
2.  Interestingly, the D103A mutant exhibited 
enhanced binding and cross-linking of VEGFR-3, 
but not VEGFR-2, compared to VEGF-DΔNΔC.  
We also analysed the capacity of selected VEGF-
D mutants to activate VEGFR-2 and VEGFR-3 on 
human adult lymphatic endothelial cells (AdLECs) 
by monitoring tyrosine phosphorylation of these 
receptors (Figure 2D).  The results were consistent 
with the ELISAs and bioassays, i.e. Y94A 
promoted phosphorylation of VEGFR-2, but not 
VEGFR-3, whereas L99A, I102A, E105A and 
W106A were unable to promote pronounced 
phosphorylation of either receptor.   
The VEGF-DΔNΔC variants studied 
above had been tagged at the N-terminus with the 
FLAG octapeptide, in relatively close proximity to 
the N-terminal α-helix, to facilitate purification 
and quantitation.  To confirm that the effects on 
receptor binding and activation we observed were 
not influenced by the FLAG-tag, we analysed the 
Y94A, K100A and I102A mutations in the setting 
of an altered form of VEGF-DΔNΔC that lacked 
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the FLAG tag.  Analysis of these mutants in 
bioassays and receptor phosphorylation assays 
showed the same profile of receptor binding, 
cross-linking and activation as for the 
corresponding FLAG-tagged mutants (Figure 3).  
These findings indicate that the FLAG tag in the 
VEGF-DΔNΔC variants did not influence the 
results of our receptor interaction studies. 
The data described above demonstrate that 
residues in the N-terminal α-helix of mature 
human VEGF-D are critical for binding VEGFR-2 
and VEGFR-3, as well as mAb 286.  Hence this 
mAb interacts with a region of VEGF-D that 
overlaps part of the binding sites for these 
receptors.  The data also suggest that the N-
terminal portion of this α-helix (i.e. from F93 to 
T98) is more important for the binding of VEGF-D 
to VEGFR-3 than to VEGFR-2. 
Distinct receptor-binding determinants in 
the N-terminal α-helices of mature VEGF-D and 
VEGF-C—Comparison of the amino acid 
sequences of the N-terminal -helices in mature 
human VEGF-C and VEGF-D indicates a high 
degree of homology between these regions with 
multiple residues that are important for the 
interaction of VEGF-D with VEGFR-2 and/or 
VEGFR-3 being conserved in VEGF-C, i.e. Y94, 
L99, I102, E105 and W106 (Figure 4A).  To 
compare the role of the α-helices in receptor 
binding we generated a series of mutants of 
VEGF-CΔNΔC and VEGF-DΔNΔC in which 
different parts of these regions were converted to 
alanine residues (these mutants are defined in 
Figure 4A).  These mutants were tested for their 
ability to activate VEGFR-2 and VEGFR-3 by 
monitoring tyrosine phosphorylation of these 
receptors.   
Mutation to alanine of all six residues N-
terminal to L99 (designated “6Ala”) in VEGF-
DΔNΔC did not alter the capacity to promote 
tyrosine phosphorylation of VEGFR-2 (Figure 4B, 
left panel).  However, additional alteration of 
either L99 (“7Ala”) or both L99 and K100 
(“8Ala”) to alanine prevented VEGFR-2 
phosphorylation.  Notably, exchange of only F93, 
Y94 and D95 to alanine (“3Ala”) in VEGF-
DΔNΔC was sufficient to prevent phosphorylation 
of VEGFR-3 (Figure 4B, right panel).  In contrast, 
for VEGF-CΔNΔC, alanine exchange of the three, 
five, six, seven or eight residues N-terminal to 
S121 (“3Ala”, “5Ala”, “6Ala’, “7Ala” or “8Ala”, 
respectively) did not have any pronounced effect 
on phosphorylation of either VEGFR-2 or 
VEGFR-3 (Figure 4C).  Likewise, a mutant of 
VEGF-CΔNΔC in which residues 113 to 121 had 
been deleted (designated “9”), induced 
phosphorylation on tyrosine of both VEGFR-2 and 
VEGFR-3, as did two mutants lacking residues 
113 to 115 or 113 to 118 (designated “3” and 
“6”, respectively) (Figure 4D).  These three 
mutants also promoted binding and cross-linking 
of the extracellular domains of VEGFR-2 and 
VEGFR-3 as assessed in bioassays (Figure 4D).   
Our studies of receptor phosphorylation 
shown in Figure 4 indicate that the N-terminal 
region of mature VEGF-D, from residues F93 to 
T98, is critical for the activation of VEGFR-3, but 
not VEGFR-2.  Surprisingly, residues in the 
homologous region of VEGF-C, i.e. from H113 to 
K120, are not critical for the activation of either 
VEGFR-2 or VEGFR-3 by this ligand.   
Key residues for driving proliferation and 
migration of LECs are distributed differently in the 
N-terminal α-helices of mature VEGF-D and 
VEGF-C—The variants of mature human VEGF-D 
described above provided the opportunity to assess 
the importance of residues in the N-terminal α-
helix for the biological activities of this growth 
factor.  Furthermore, given that these variants 
exhibited distinct receptor-binding specificities, 
they could also be used to assess the role of 
VEGFR-2 and VEGFR-3 in the bioactivities of 
VEGF-D.  We focussed on the proliferation and 
migration of LECs because these processes are 
required for the remodelling of lymphatics in 
cancer which in turn promotes metastatic spread 
via the lymphatic vasculature (1).  Migration of 
neonatal human dermal microvascular LECs was 
monitored in a scratch wound assay - see 
Experimental Procedures for details of the 
protocol.  As expected, VEGF-DΔNΔC, which 
activates VEGFR-2 and VEGFR-3, promoted both 
proliferation and migration of LECs; these effects 
of VEGF-D were blocked by mAb 286 (Figure 
5A-C).  In contrast, VEGF-DΔNΔC variants 
Y94A, 3Ala, 5Ala and 6Ala, all of which activate 
VEGFR-2 but not VEGFR-3, promoted 
proliferation but not migration of LECs (Figure 
5A-C).  Moreover, VEGF-DΔNΔC variants L99A, 
7Ala and 8Ala, which do not activate either 
VEGFR-2 or VEGFR-3, did not promote either 
proliferation or migration of LECs.  VEGF-
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CΔNΔC, like VEGF-DΔNΔC, promoted both 
proliferation and migration of LECs in these 
assays.  But in contrast to VEGF-D, the 3Ala, 
5Ala, 6Ala, 7Ala and 8Ala variants of VEGF-
CΔNΔC (which activate both VEGFR-2 and 
VEGFR-3) all promoted proliferation and 
migration of LECs (Figure 5A-C).  These data 
further confirm that the N-terminal region of 
mature VEGF-D, from residues F93 to T98, is a 
critical determinant of biological activity whereas 
this is not the case for the homologous region of 
mature VEGF-C.  Our findings also emphasize the 
importance of VEGFR-2 signalling for 
proliferation of LECs, and of VEGFR-3 signalling 
for migration of these cells. 
Enhancing the capacity of VEGF-D to 
activate VEGFR-3 promotes expression of COX-2 
in LECs—The VEGF-D variant D103A exhibited 
stronger activity than VEGF-DΔNΔC in assays of 
binding, cross-linking and tyrosine 
phosphorylation of VEGFR-3 (Figure 2B-D).  To 
explore this further we titrated D103A and VEGF-
DΔNΔC in the bioassays of VEGFR-2 and 
VEGFR-3 binding and cross-linking.  This 
analysis confirmed that D103A was more potent in 
the VEGFR-3 bioassay than VEGF-DΔNΔC, 
whereas these two proteins exhibited comparable 
potency in the VEGFR-2 bioassay (Figure 6A).  
The data in Figures 2B-D and 6A show that the 
D103A mutant of VEGF-DΔNΔC allows 
assessment of the functional consequences of 
specifically enhancing the capacity of mature 
VEGF-D to activate VEGFR-3.   
It was previously shown in an animal 
model of cancer that tumor-derived VEGF-C 
promoted expression of COX-2 in the endothelial 
cells of collecting lymphatic vessels whereas 
VEGF-D did not, indicating distinct molecular 
mechanisms by which these two growth factors 
promote metastasis via lymphatics (5).  Likewise, 
when AdLECs were treated in vitro with 100 
ng/ml of VEGF-CΔNΔC and VEGF-DΔNΔC, 
only the former induced higher levels of mRNA 
for COX-2 as assessed by quantitative RT-PCR 
(Figure 6B).  Treatment with the 3Ala variant of 
VEGF-CΔNΔC, which activates VEGFR-2 and 
VEGFR-3, also increased levels of COX-2 mRNA 
in AdLECs.  In contrast, the L99A variant of 
VEGF-DΔNΔC, which exhibits decreased binding 
to both VEGFR-2 and VEGFR-3, did not alter the 
level of COX-2 mRNA nor did treatment with the 
3Ala variant of VEGF-DΔNΔC which activates 
VEGFR-2 but not VEGFR-3.  Unexpectedly, 
treatment of LECs with the D103A variant of 
VEGF-DΔNΔC was able to induce increased 
levels of COX-2 mRNA, in contrast to VEGF-
DΔNΔC (Figure 6B).  This indicates that 
enhancing the potency of VEGF-D for VEGFR-3 
activation promotes the capacity of this growth 
factor to drive increased expression of COX-2 by 
LECs.   
In order to explore why VEGF-CΔNΔC at 
100 ng/ml promoted COX-2 expression in LECs 
but VEGF-DΔNΔC did not, we conducted 
titrations of these ligands in this assay, and in the 
bioassay of VEGFR-3 binding and cross-linking.  
This showed that VEGF-CΔNΔC is approximately 
ten-fold more potent than VEGF-DΔNΔC for 
binding and cross-linking VEGFR-3, and for 
inducing COX-2 expression (Figure 6C).  These 
data demonstrate that VEGF-DΔNΔC can induce 
increased expression of COX-2 in LECs, but only 
at higher ligand concentrations than for VEGF-
CΔNΔC.  Overall, these findings show that the 
potency of VEGF family ligands for activating 
VEGFR-3 correlates with the capacity to promote 
expression of COX-2 in LECs.   
Enhancing the capacity of VEGF-D to 
activate VEGFR-3 promotes lymphatic 
sprouting—We assessed the D103A variant of 
VEGF-DΔNΔC in a model of sprouting 
lymphangiogenesis in the ears of mice, to monitor 
in vivo effects of specifically enhancing the 
capacity of VEGF-D to activate VEGFR-3.  This 
model involves delivery of VEGF-D to initial 
lymphatics in the dermis of adult skin via 
intradermal injection in the presence of Matrigel 
(see Experimental Procedures).  Treatment with 
VEGF-DΔNΔC led to lymphatic vessels with 
more sprouts and a larger mean width than the 
PBS negative control (Figure 6D); the increase in 
mean vessel width was statistically significant.  
Notably, the D103A variant induced a very large 
number of sprouts on lymphatics, statistically 
significantly more than those induced by VEGF-
DΔNΔC.  However, the mean width of lymphatics 
in ears treated with D103A was comparable to 
those treated with VEGF-DΔNΔC.  These data 
indicate that the D103A mutant is advantageous 
for promoting lymphangiogenic sprouting in vivo.  
This finding is consistent with our data showing 
that this variant drives enhanced migration and 
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proliferation of LECs in vitro, compared to VEGF-
DΔNΔC (see Fig. 5A and B) – both of these 
processes would be required for lymphatic 
sprouting based on analogy to angiogenic 
sprouting (40).  These findings suggest that the 
D103A variant of VEGF-DΔNΔC may be useful 
for promoting therapeutic lymphangiogenesis 
designed to enhance lymphatic function in disease 
settings. 
 
DISCUSSION 
This study explores the molecular basis 
underlying functional differences between VEGF-
C and VEGF-D.  The starting point was to better 
define the interaction of VEGF-D with its 
receptors given that, in contrast to VEGF-C, there 
have been no reports of structures for VEGF-D in 
complex with either VEGFR-2 or VEGFR-3.  We 
used the neutralizing VEGF-D mAb 286 to 
identify a region of this growth factor, in the N-
terminal -helix of the mature form, which is 
important for receptor binding.  Some of the single 
alanine substitutions we generated in the mAb 286 
binding epitope prevented binding of VEGF-D to 
VEGFR-2 and VEGFR-3 indicating that mAb 286 
targets a region required for receptor binding 
rather than acting via steric hindrance.  We 
identified an amino acid residue in the α-helix, 
Y94, that is critical for activating VEGFR-3 but 
not VEGFR-2, and showed that residues L99, 
I102, E105 and W106 are important for binding 
both receptors.  Surprisingly, the region of VEGF-
C homologous to residues F93 to K100 of VEGF-
D (i.e. VEGF-C residues H113 to K120) is not 
required for binding VEGFR-2 or VEGFR-3, nor 
for VEGF-C to drive proliferation or migration of 
LECs.  This is supported by our observation that a 
mutant of mature VEGF-C, in which residues 113 
to 121 were deleted, is able to activate VEGFR-2 
and VEGFR-3.  These findings show that an N-
terminal portion of the α-helix in mature VEGF-D 
(T92 to T98) is important for binding VEGFR-3 
but not VEGFR-2 whereas the remainder of this 
helix (L99 to T109) is important for binding both 
receptors.  In contrast, the corresponding N-
terminal portion of the α-helix in mature VEGF-C 
(H113 to S121) is dispensable for binding either 
receptor.  It has been shown that some residues 
(e.g. D123, W126 and R127) in the remainder of 
the α-helix of mature VEGF-C (I122 to T129) are 
important for binding VEGFR-2 and/or VEGFR-3 
(36,37).  These observations raise the possibility of 
post-translational regulatory mechanisms targeting 
the N-terminal portions of the α-helices that could 
exert distinct effects on the receptor-binding 
specificities and biological activities of VEGF-C 
and VEGF-D.   
Cleavage of the C-terminal propeptide 
from the VHD of VEGF-D occurs after residue 
R205 (25).  Two forms of mature VEGF-D can 
then be generated by two distinct cleavage events 
that remove the N-terminal propeptide, one giving 
rise to an N-terminus at F89 (VEGF-D89-205), the 
other at K100 (VEGF-D100-205) (25).  Our results 
suggest that these two derivatives exhibit different 
receptor binding specificities – VEGF-D89-205 
would activate both VEGFR-2 and VEGFR-3 
whereas VEGF-D100-205 would not activate 
VEGFR-3.  Further, our data on the importance of 
L99 for the VEGFR-2 interaction suggest that 
VEGF-D100-205 would exhibit reduced binding and 
activation of VEGFR-2 compared to VEGF-D89-
205.  These predictions are broadly consistent with 
a previous study showing that a variant of VEGF-
D89-195, with a C117A mutation, could activate 
both VEGFR-2 and VEGFR-3 (32).  In contrast, a 
C117A variant of VEGF-D100-195 was barely able 
to bind and cross-link the VEGFR-3 extracellular 
domain in bioassays and exhibited much weaker 
potency for activating VEGFR-3 than the C117A 
variant of VEGF-D89-195.  The VEGF-D100-195 
variant exhibited lower potency for binding and 
cross-linking of the VEGFR-2 extracellular 
domain compared to the VEGF-D89-195 variant, as 
expected based on our data, but was able to 
activate this receptor.  The capacity of this VEGF-
D100-195 variant to activate VEGFR-2, in contrast to 
the L99A mutant reported here, may in part be due 
to the C117A mutation which can increase the 
bioactivity of VEGF-D (the comparable mutation 
in VEGF-C has similar effects) (41-44).  Overall, 
it is clear that the choice of site at which the N-
terminal propeptide is cleaved influences receptor-
binding specificity of the resulting mature form of 
VEGF-D.   
Proteolytic cleavage of VEGF-C to 
remove the N-terminal propeptide was previously 
reported to occur at two distinct sites immediately 
after residue 102 or 111 (29).  These sites are some 
considerable distance N-terminal to residues in the 
α-helix of mature VEGF-C important for receptor 
binding (e.g D123 and R127) (36,37), so the 
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choice between these sites is unlikely to alter the 
receptor-binding specificity of mature VEGF-C.  
However, it has recently been reported that 
incubation of VEGF-C in vitro with high 
concentrations of plasmin leads to cleavage of the 
N-terminal propeptide between residues 127 and 
128, thus removing almost the entire N-terminal α-
helix of mature VEGF-C and generating a protein 
incapable of activating VEGFR-3 (45).  In 
contrast, more limited exposure to plasmin 
generated VEGF-C able to activate VEGFR-3 
(28,45), although the cleavage site involved has 
not been reported.  Hence it is possible that distinct 
sites could be used for cleavage of the N-terminal 
propeptide in vivo leading to different receptor 
specificities for the resulting forms of mature 
VEGF-C.  The locations of the cleavage sites in 
VEGF-C and VEGF-D utilized in cancer and other 
pathologies have not yet been systematically 
investigated. 
The importance of VEGFR-3 signaling for 
sprouting lymphangiogenesis is supported by our 
findings that mutants of VEGF-DΔNΔC deficient 
for VEGFR-3 activation (but which could activate 
VEGFR-2), e.g. Y94A, 3Ala, 5Ala and 6Ala, were 
unable to promote migration of LECs in contrast to 
VEGF-DΔNΔC.  Further, the D103A mutant, 
which has increased potency for binding and 
cross-linking VEGFR-3, had enhanced capacity to 
promote sprouting of lymphatics in vivo compared 
to VEGF-DΔNΔC.  These findings are consistent 
with previous reports that mature VEGF-C, which 
binds both VEGFR-2 and VEGFR-3, can potently 
induce lymphatic sprouting and lymphagiogenesis, 
and that VEGFR-3-specific variants of VEGF-C or 
VEGF-D also promote lymphangiogenesis (32,46).  
The VEGF-DΔNΔC variants Y94A, 3Ala, 5Ala 
and 6Ala were able to promote proliferation of 
LECs in vitro and enlargement of lymphatic 
vessels in vivo which is consistent with the notion 
that VEGFR-2 signaling promotes lymphatic 
vessel enlargement, as proposed previously (47).  
Our data also suggest that VEGFR-3 activation is 
important for driving increased levels of COX-2 
mRNA in LECs which is relevant to tumor biology 
given that COX-2 can be important for tumor-
associated lymphangiogenesis, dilation of 
collecting lymphatic vessels and metastatic spread 
(5,48).  Both VEGF-CΔNΔC and the D103A 
mutant of VEGF-DΔNΔC, which exhibit enhanced 
potency for activating VEGFR-3 compared to 
VEGF-DΔNΔC, also exhibited enhanced potency 
for inducing increased COX-2 expression in LECs 
compared to VEGF-DΔNΔC.  This suggests that 
the potency of a VEGF ligand for activating 
VEGFR-3 is an important determinant of its 
potency for driving enhanced COX-2 expression in 
LECs.  An alternative explanation for these 
findings is that VEGF-CΔNΔC, and the D103A 
mutant of VEGF-DΔNΔC, can engage co-
receptors or other signalling molecules in LECs 
(2,49) that facilitate up-regulation of COX-2 
expression, whereas VEGF-DΔNΔC cannot or 
does so less effectively.  The mechanistic role of 
COX-2 in tumor lymphangiogenesis, and the 
potential involvement of this protein in lymphatic 
sprouting, are important issues that require further 
investigation in in vitro and in vivo models of 
lymphatic remodelling. 
Our data complement a previous study, 
employing an alternative neutralizing VEGF-D 
mAb, that identified a region of loop L2 of mature 
VEGF-D (N147 to L151) as critical for binding 
both VEGFR-2 and VEGFR-3 (38).  The 
importance of this region in loop L2 for receptor 
interactions, as well as of the -helix as indicated 
here, is consistent with the crystal structure of 
VEGF-C in complex with regions of VEGFR-2 
and VEGFR-3 (36,37).  In particular, the VEGF-
C/VEGFR-2 complex allowed identification of an 
interface on VEGF-C, important for binding 
VEGFR-2, consisting of the N-terminal -helix 
and the region of loop L2 from N167-L171.  This 
region of loop L2 in VEGF-C is homologous to 
residues N147 to L151 in loop L2 of VEGF-D.  
Thus the same region of loop L2 is important for 
both VEGF-C and VEGF-D to bind receptors.  
The -helix is also critical but our data shows that 
the distribution of residues in the helix that are 
important for the VEGFR-3 interaction is different 
in VEGF-C and VEGF-D.   
There is considerable interest in 
therapeutically targeting VEGF-C and/or VEGF-D 
in the clinic to block their action and thereby 
restrict angiogenesis, lymphagiogenesis or 
vascular leakage in cancer, macular degeneration 
and other conditions (9,50-53).  The VEGF-D 
mAb 286 characterised here, which blocks the 
binding and cross-linking of VEGFR-2 and 
VEGFR-3 by VEGF-D as well as the proliferation 
and migration of LECs induced by VEGF-D, could 
facilitate development of therapeutic monoclonal 
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antibodies that block the action of VEGF-D, or of 
bispecific antibodies that target both VEGF-D and 
VEGF-C.  Such therapeutic antibodies could 
potentially be used in human cancer to restrict 
tumor angiogenesis, lymphangiogenesis and 
lymphatic remodelling, and thereby inhibit tumor 
growth and spread.  Conversely, the delivery of 
VEGF family growth factors into tissues has the 
potential to promote therapeutic angiogenesis or 
lymphangiogenesis for treating cardiovascular 
conditions, lymphedema and inflammatory 
diseases (9,50,54-60).  Our finding that the D103A 
mutant of mature VEGF-D exhibits enhanced 
potency for VEGFR-3 could be of clinical 
significance as this protein, or derivatives thereof, 
could potentially be used therapeutically to drive 
lymphangiogenesis and lymphatic remodelling in 
lymphedema and inflammatory conditions.  The 
aim of this approach would be to promote 
enhanced lymphatic function that has already been 
shown to be beneficial in clinically relevant animal 
models of these conditions (59,61).  Development 
of clinical agents designed to modulate the 
function of lymphatic vessels may have impact in 
multiple prevalent human diseases and is a high 
priority for the future. 
 
EXPERIMENTAL PROCEDURES 
Monoclonal antibodies—Monoclonal 
antibody (mAb) 286 was from R&D Systems 
(Minneapolis, MN, USA) and VD1 (a neutralizing 
VEGF-D mAb) and VD4 (a mAb that binds, but 
does not neutralize, VEGF-D) have been described 
previously (39). 
Protein constructs—VEGF-DΔNΔC is a 
recombinant form of mature human VEGF-D that 
contains residues 93-201 of this growth factor, and 
is N-terminally tagged with the FLAG octapeptide 
(22,25).  Likewise, VEGF-CΔNΔC is a form of 
mature VEGF-C containing residues 102-229 
tagged with FLAG at the N-terminus.  
Recombinant human VEGFR-2- and VEGFR-3-Fc 
chimeras (catalogue numbers 357-KD-050 and 
349-F4-050, respectively) were from R&D 
Systems (Minneapolis, MN, USA). 
Site-directed mutagenesis—Mutations of 
VEGF-C and VEGF-D were made in the regions 
113HYNTEILKSIDNEWR127 and 
93FYDIETLKVIDEEWQR108, respectively.  Single 
mutations or mutations of multiple residues were 
introduced into constructs encoding FLAG-tagged 
or untagged VEGF-CNC or VEGF-DNC by 
amplification with specifically designed primers 
(see Supplementary Table 1 for primers).  All 
mutations were confirmed by nucleotide 
sequencing. 
Protein expression and purification—
Plasmids encoding VEGF-CΔNΔC, VEGF-
DΔNΔC or their variants were used for transient 
transfection of 293-F cells with the FreeStyle™ 
MAX 293 Expression System according to 
manufacturer's instructions (Invitrogen, Carlsbad, 
CA, USA).  Cells expressing each variant were 
cultured in serum-free medium, and 30 ml of 
conditioned media were collected 7 days post- 
transfection and used for analysis.  Protein 
expression was tested by Western blotting with 
M2 anti-FLAG antibody or, for VEGF-D, with a 
mAb that targets the VHD (MAB2861, R&D 
Systems).  Proteins were purified from conditioned 
media by affinity chromatography on M2 (anti-
FLAG) gel as described previously (25).  Equal 
volumes of conditioned media containing VEGF-
DΔNΔC variants that were not tagged with the 
FLAG peptide were concentrated to the same final 
volume and buffer exchanged into PBS using an 
Amicon size exclusion centrifugal filter with a 10 
kDa Nominal Molecular Weight Limit (Millipore, 
Billerica, MA, USA).  The purity and 
concentrations of VEGF-C and VEGF-D variants 
were determined by Coomassie Brilliant Blue 
staining (see Supplementary Figure 1) and/or 
Western blotting compared to VEGF-C or VEGF-
D standards of known concentration.  
Densitometry was performed using an Odyssey 
Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE, USA). 
Western blotting—Variants of VEGF-
DΔNΔC were resolved by SDS-PAGE, transferred 
to nitrocellulose membrane, probed with M2 anti-
FLAG antibody (Sigma Aldrich, St. Louis, MO, 
USA) or mAb 286 labelled with 800 IRDye® 
according to manufacturer’s instructions (LI-COR 
Biosciences, Lincoln, NE, USA), and detected 
with an Odyssey Infrared Imaging System.  SDS-
PAGE was carried out under reducing and 
denaturing conditions.  Western blotting analysis 
to detect receptor phosphorylation was as 
described previously (62).  For all Western blot 
panels shown in figures, each experiment was 
performed at least three times, and the same 
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effects shown in blots were observed each time the 
experiments were conducted. 
ELISAs for peptide screening and analyses 
of ligand binding by antibodies and receptors—
For screening a synthetic biotinylated peptide 
library encompassing the VHD of VEGF-D (38), 
streptavidin high-binding-capacity coated plates 
(Reacti-Bind™, Pierce, Rockford, IL, USA) were 
incubated with 10 pmol of each peptide in PBS.  
Peptides were then blocked with 1% BSA in PBS 
containing 0.1% Tween 20, and incubated with 
100 µl of either mAb 286 or M2 anti-FLAG 
antibody (2 µg/ml) for 1 hour at room temperature 
(RT).  Bound mAb was detected with goat anti-
mouse IgG coupled with horse-radish peroxidise 
(HRP).  Background was defined as signal 
detected in the absence of both antibody and 
peptide.   
For analysis of binding of mAb 286 to 
VEGF-DΔNΔC variants, microtitre plates 
(Linbro®/Titertek®, ICN Biomedicals Inc., 
Aurora, OH, USA) were coated with mAb 286 at 5 
µg/ml in 100 mM carbonate buffer pH 9.5, then 
blocked with 1% BSA in PBS-0.1% Tween 20, 
and incubated with 100 µl of serum-free cell 
culture media containing 100 ng of VEGF-
DΔNΔC variants for 1 h at RT.  Bound VEGF-
DΔNΔC was detected with an anti-VEGF-D 
antibody designated VD1 (39) coupled with HRP.  
For testing receptor binding, microtitre 
plates were coated with human VEGFR-2- or 
VEGFR-3-Fc chimeras at 0.5 µg/ml in 100 mM 
carbonate buffer pH 9.5, then blocked with 1% 
BSA in PBS-0.1% Tween 20, and incubated with 
100 µl of PBS containing 20 ng of purified VEGF-
C or VEGF-D variants for 1 h at RT.  Bound 
ligands were detected with M2-HRP (Sigma-
Aldrich, St. Louis, MO, USA) at 2 µg/ml for 1 h at 
RT.  Assays were developed with an ABTS 
substrate system (Zymed, Carlsbad, CA, USA) or 
with PrestoBlue™ Cell Viability Reagent 
(Invitrogen) and quantified by monitoring 
absorbance according to manufacturers’ 
instructions. 
Bioassays for binding and cross-linking of 
extracellular domains of VEGFR-2 or VEGFR-3—
Bioassays employed cell lines expressing chimeric 
receptors consisting of the entire extracellular 
domain of mouse VEGFR-2 or human VEGFR-3 
and the trans-membrane and cytoplasmic domains 
of the mouse erythropoietin receptor (25,63).  
Binding and cross-linking of the chimeric 
receptors allows these cells to survive and 
proliferate in the absence of interleukin-3 (IL-3).  
Bioassays with VEGF-C and VEGF-D variants 
were conducted as described previously (25,64) 
except that the ligand concentration was 200 ng/ml 
(unless specified otherwise) and DNA synthesis or 
proliferation of cells was monitored using 3H-
thymidine (65), or a ViaLight Plus Kit (Lonza, 
Basel, Switzerland) or Presto Blue™ Cell Viability 
Reagent (Invitrogen, Carlsbad, CA, USA) 
according to manufacturers’ protocols.  For some 
assays, mAbs VD1 and VD4 were included as 
controls.  
Receptor phosphorylation assays—
Phosphorylation of VEGFR-2 and VEGFR-3 on 
adult LECs (AdLECS, Lonza, Basel, Switzerland) 
treated with VEGF-C or VEGF-D variants at 200 
ng/ml was analysed as previously described (62). 
Quantitative RT-PCR to analyse COX-2 
mRNA—AdLECS were serum-starved overnight, 
then exposed to VEGF-C or VEGF-D variants (at 
100 ng/ml, unless stated otherwise) prior to 
isolation of total RNA using an RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA), and preparation of 
cDNA with a High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) using 1 µg of total RNA.  
Quantitation of cDNA for COX-2 and the internal 
reference gene (-actin) was carried out with a 
TaqMan Fast Universal PCR Master Mix using an 
Applied Biosystems 7500 Fast Real-Time PCR 
machine (both from Thermo Fisher Scientific).  
TaqMan gene expression assays for COX-2 
(HS00153133-M1) and -actin 
(HS99999903_M1) were from Applied 
Biosystems (Thermo Fisher Scientific).  Each 
reaction was done in triplicate and all samples 
were analyzed using StepOneTM Software v2.2 
(Thermo Fisher Scientific).  Quantitation of COX-
2 mRNA after treatment of cells with growth 
factors, relative to untreated control cells, was 
determined by the ΔCT method.  Data are 
presented as mean ± SD of three independent 
experiments, and statistical analysis was with the 
Student’s t test. 
Cell migration assay—The migration of 
neonatal human dermal lymphatic microvascular 
endothelial cells (Clonetics, HMVEC-dLyNeo, 
Lonza) was assessed in a scratch wound assay.  
Cells were cultured in EGMTM-2MV growth 
 at K
IN
G
'S CO
LLEG
E LO
N
D
O
N
 on N
ovem
ber 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Distinct receptor binding and function of VEGF-C and VEGF-D 
 10
medium (Lonza) with 5% FBS and supplements 
according to manufacturer’s instructions in 
humidified 5% CO2 at 37°C.  Cells (1 × 104) were 
seeded in 96-well clear-bottom imaging plates 
(Greiner Bio One, Frickenhausen, Germany) 
coated with 5 µg/ml fibronectin and grown to 
confluency.  Prior to scratch wounding of the 
monolayer, cells were stained with Celltracker™ 
Green CMFDA (Invitrogen, Thermo Fisher 
Scientific) for 45 min at 37°C, and a 96-pin 
wounding device (V&P Scientific, San Diego, CA, 
USA) was used to create a uniform scratch (~0.5 
mm x 5 mm).  Immediately post-wounding, 
variants of VEGF-C and VEGF-D (200 ng/ml) in 
EBM-2 basal medium (Lonza) supplemented with 
2% FBS were added to the cells and each well was 
imaged using a BD Pathway 435 high-throughput 
bio-imager (BD Biosciences, Franklin Lakes, NJ, 
USA).  The entire wound was captured using a 2 × 
1 montage with a Nikon 4× objective.  After 24 
hours, cells were fixed with 4% paraformaldehyde 
(ProSciTech, Thuringowa, Queensland, Australia), 
blocked and permeabilised in PBS containing 
0.2% Triton-X and 2% BSA, stained with 
Phalloidin Alexa 488 (Invitrogen, Thermo Fisher 
Scientific) and imaged as above.  Captured images 
were exported to Metamorph® (Molecular 
Devices, Sunnyvale, CA, USA) or to FIJI (66) 
image processing software packages for analysis 
of wound closure using custom-designed macros. 
Cell proliferation assays—AdLECs were 
grown to 90% confluence and starved overnight in 
EGMTM-2MV growth medium (Lonza) containing 
2% FBS, 50 μg/ml Gentamicin and 2.5 μg/ml 
Amphotericin B.  Cells were trypsinized, counted 
and approximately 1.5 × 104 cells were 
resuspended in 100 μl of medium containing 
VEGF-C or VEGF-D variants at 200 ng/ml.  Cells 
were plated on wells of a clear-bottom 96-well 
microplate (BD Biosciences) that had been coated 
with 5 μg/ml fibronectin and then incubated for 
four days. Cells were replenished at the two-day 
time-point with medium containing VEGF-C or 
VEGF-D variants.  Cell proliferation was 
determined using CellTiter96®AQueous One 
Solution Cell Proliferation Assay Reagent 
(Promega, Madison, WI, USA) as described by the 
manufacturer.   
Delivery of VEGF-D variants in vivo—
Dermal delivery of purified VEGF-D variants in 
Matrigel plugs was performed essentially as 
documented (67) except that purified VEGF-D 
variants (1 g) in 20 μl of PBS were mixed with 
30 μl of Matrigel prior to injection (i.e. the variants 
were at 20 g/ml in the injection solution).  
VEGF-D variants were injected subcutaneously 
every 24 h for 3 days. 
Mice—SCID/NOD mice (8-week old 
females) were from the Australian Resource 
Centre (Perth, WA, Australia).  Experiments were 
conducted according to ethical guidelines of the 
National Health and Medical Research Council of 
Australia and the Animal Ethics Committee of the 
Peter MacCallum Cancer Centre. 
Structural prediction of mAb 286 binding-
site in N-terminal α-helix of mature VEGF-D—
The structure of the N-terminal α-helix 
(93FYDIETLKVIDEEWQ107) in human mature 
VEGF-D (presented in Figure 2A), including the 
mAb 286 binding-site, was generated from 
available crystallographic data for VEGF-D 
(PDB:2XV7) (32), with addition and optimization 
of missing side chains, using PyMol (PyMOL 
Molecular Graphics System, Version 1.3.x 
Schrödinger, New York, NY, USA). 
Statistical analysis—All statistical 
comparisons were based on one-way analysis of 
variance using Tukey’s Post-Hoc Test with 
significance level (alpha) at 0.05.  Statistical 
analyses were performed with Graph Pad Prism 
Version 6.07 (GraphPad Software, La Jolla, CA, 
USA). 
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FIGURE LEGENDS 
 
FIGURE 1.  Neutralizing effect of mAb 286, mapping of its binding-site and analysis of binding to 
VEGF-D variants with mutated residues in N-terminal α-helix.  A. The capacity of mAb 286 to block 
binding and cross-linking, by VEGF-DΔNΔC, of chimeric receptors containing VEGFR-2 (left) or 
VEGFR-3 (right) extracellular domains was assessed in bioassays (see Experimental Procedures).  Also 
included were neutralizing mAb VD1, that binds loop 2 of VEGF-DΔNΔC, and mAb VD4 that binds, but 
does not neutralize, VEGF-DΔNΔC (39).  B. Peptide-based mapping of mAb 286 binding-site in VEGF-
DΔNΔC by ELISA (see Experimental Procedures).  The ratio of signal to background for interaction of 
mAb 286 with immobilised peptides is shown on the y-axis of the graph and the x-axis defines identifier 
numbers of peptides.  Upper box above graph: amino acid sequence for VEGF homology domain of 
human VEGF-D – N-terminal residue (phenylalanine) is number 89 and C-terminal residue (arginine) is 
205.  Lower box above graph: examples of peptides used in mapping (mAb 286 binding-site is in 
rectangle).  FLAG sequence is shown in bold in peptide 36, which lacks VEGF-D-derived sequence, and 
was the negative control.  C. Detection of VEGF-DΔNΔC variants by Western blot under reducing and 
denaturing conditions using mAb 286 (top) or M2 anti-FLAG mAb as positive control (bottom).  Each 
well contained 30 ng of purified protein.  “VEGF-D” denotes VEGF-DΔNΔC, and variants of this protein 
each have one residue mutated to alanine, as indicated.  Positions of molecular weight markers (in kDa) 
are shown to the left.  Histogram under the blots shows intensities of bands for VEGF-D variants 
(mean±standard deviation) relative to the intensity of the band for VEGF-DΔNΔC, as determined from 
Western blots with mAb 286.  D. Analysis of mAb 286 binding to VEGF-DΔNΔC variants by ELISA.  
M2 was used for capture and mAb 286 for detection; y-axis shows binding of variant proteins compared 
to VEGF-DΔNΔC (the latter defined as 100% binding), and x-axis lists VEGF-D variants.  Equal 
amounts of VEGF-DΔNΔC and variants were used.  For A, B and D, assays were conducted three times – 
columns denote mean and error bars denote standard deviation. 
 
 
FIGURE 2.  Interaction of VEGFR-2 and VEGFR-3 with VEGF-DΔNΔC variants.  A. 
Representation of structure for part of the N-terminal α-helix (93FYDIETLKVIDEEWQ107) in human 
mature VEGF-D with mAb 286 binding-site shown in red.  B. Analysis of binding of VEGF-DΔNΔC 
variants to VEGFR-2 (left) and VEGFR-3 (right) by ELISA (see Experimental Procedures).  Y-axes show 
binding of variant proteins compared to VEGF-DΔNΔC (the latter defined as 100%), and x-axes define 
the mutated amino acid in each variant.  The same amount of each VEGF-DΔNΔC variant was used.  
“VEGF-D” denotes VEGF-DΔNΔC.  Assays were conducted three times – columns show the mean and 
error bars denote standard deviation.  C. Bioassays for binding and cross-linking of the extracellular 
domains of VEGFR-2 (left) and VEGFR-3 (right) by VEGF-DΔNΔC variants.  The same amount of each 
VEGF-DΔNΔC variant was used in each assay.  Results are expressed as percentage of fluorescence units 
generated by VEGF-DΔNΔC variants relative to VEGF-DΔNΔC (y-axes).  X-axes define the mutated 
amino acid in each variant.  Assays were conducted five times – columns show mean and error bars 
denote standard deviation.  D. Receptor phosphorylation induced by selected VEGF-DΔNΔC variants.  
Adult LECs were stimulated with matched quantities of VEGF-D∆N∆C or its variants or left 
unstimulated (No GF).  Lysates were immunoprecipitated with an antibody against VEGFR-2 (left) or 
VEGFR-3 (right) and analysed by reducing SDS-PAGE and Western blotting with an antibody against 
phosphotyrosine (pY) to assess activation of receptors (top blot in each pair), or with an antibody against 
VEGFR-2 (bottom blot in each pair on the left), or VEGFR-3 (right bottom blot) to confirm the presence 
of each receptor.  VEGFR-2 migrated predominantly at ~230 kDa whereas VEGFR-3 migrated as three 
bands, a ~125 kDa cleaved form, and two uncleaved forms of ~175 kDa and ~195 kDa that differ in 
degree of glycosylation.  Sizes of molecular weight markers (in kDa) are shown to the left of panels.  
Dotted lines indicate where irrelevant tracks have been excised from images. 
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FIGURE 3.  Receptor binding and activation by untagged VEGF-D variants.  A. Bioassays for 
binding and cross-linking of extracellular domains of VEGFR-2 (left) and VEGFR-3 (right) with altered 
versions of VEGF-DΔNΔC, Y94A, K100A and I102A lacking FLAG tag.  The same amount of each 
VEGF-DΔNΔC variant was used.  Results are expressed as percentage of fluorescence units generated 
relative to untagged VEGF-DΔNΔC (y-axis).  “VEGF-D” denotes the untagged form of VEGF-DΔNΔC.  
Assays were conducted three times – columns show mean and error bars denote standard deviation.  
Asterisks indicate statistically significant differences as assessed by one-way analysis of variance with 
Tukey’s Post-Hoc Test.  B. Adult LECs were stimulated with matched quantities of untagged variants or 
left unstimulated (No GF).  Lysates were immunoprecipitated with antibody against VEGFR-2 (left) or 
VEGFR-3 (right) and analysed by reducing SDS-PAGE and Western blotting with antibody against 
phospho-tyrosine to assess receptor activation (top blots), or with antibody against VEGFR-2 (left bottom 
blot) or VEGFR-3 (right bottom blot) to confirm presence of each receptor.  Sizes of molecular weight 
markers (in kDa) are shown to the left of panels. 
 
 
FIGURE 4.  Effects of mutating residues in N-terminal α-helices of VEGF-DΔNΔC or VEGF-
CΔNΔC.  A. Sequences within the N-terminal α-helices of human VEGF-DΔNΔC (“VEGF-D”) and 
VEGF-CΔNΔC (“VEGF-C”) (top, with identical residues underlined) with variants in which multiple 
residues were altered to alanine shown underneath.  B and C. Blots show analyses of receptor 
phosphorylation by variants of VEGF-DΔNΔC and VEGF-CΔNΔC, respectively.  D. Blots show analyses 
of receptor phosphorylation induced by VEGF-CΔNΔC and mutants of VEGF-CΔNΔC lacking residues 
113 to 115 (designated 3), 113 to 118 (6) and 113 to 121 (9).  Graphs below blots show results of 
bioassays of binding and cross-linking of VEGFR-2 and VEGFR-3 extracellular domains by VEGF-C 
variants (data are mean percentage of fluorescence relative to VEGF-CΔNΔC ± standard deviation).  For 
blots in B-D, adult LECs were stimulated with VEGF-DΔNΔC, VEGF-CΔNΔC or their variants, or left 
unstimulated (No GF).  Lysates were immunoprecipitated with antibody against VEGFR-2 (left-side 
blots) or VEGFR-3 (right-side blots) and analysed by reducing SDS-PAGE and Western blotting with 
antibody against phospho-tyrosine to assess receptor activation (top blots), or with antibody against 
VEGFR-2 (left bottom blots) or VEGFR-3 (right bottom blots) to confirm the presence of each receptor.  
Sizes of molecular weight markers (in kDa) are shown to the left of blots.  The amounts of VEGF-D or 
VEGF-C variants were matched in each experiment.  Dotted lines indicate where irrelevant tracks have 
been excised from the images.  In C and D, numbers under lanes of blots represent the ratios of the 
intensities of phosphorylated receptor signals to intensities of total receptor signals (“[PO4]:[Total]”) for 
each ligand treatment as determined by calculating the mean ratios from two independent experiments.  
The ratios for VEGFR-2 were derived by combining the intensities of the signals for bands in the size 
range of 188-230 kDa (N.B.: the lower band of ~125 kDa in the left, upper blot of panel C was not used 
as it likely represents co-immunoprecipitated VEGFR-3 arising from receptor heterodimers, as reported 
previously(68)) whereas those for VEGFR-3 are based on combining the intensities of the ~125, ~175 and 
~195 kDa forms of this receptor. 
 
 
FIGURE 5.  Analyses of the role of N-terminal α-helices of mature VEGF-D and VEGF-C for 
proliferation and migration by LECs.  A. LEC proliferation assays.  Adult LECs were treated with 
VEGF-DΔNΔC (“VEGF-D”), VEGF-CΔNΔC (“VEGF-C”) or their variants, or left untreated (No GF); 
“VEGF-D+286” denotes the combination of VEGF-DΔNΔC and a 10-fold molar excess of mAb 286.  Y-
axes represent proliferation by LECs stimulated with growth factor relative to that of un-stimulated cells.  
X-axes denote VEGF-D variants (left) and VEGF-C variants (right) used in assays.  B. LEC migration 
assay.  The capacity of variant proteins to induce cell migration was assessed in a scratch wound assay.  
Neonatal LECs were wounded and the amount of wound closure was calculated for each variant as 
described in Experimental Procedures.  Y-axes show migration of cells stimulated with growth factor 
relative to that of unstimulated cells.  X-axes denote VEGF-D variants (left) and VEGF-C variants (right) 
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used in assays.  C. Images of selected scratch wounds.  Wounds were imaged immediately post-wounding 
(“T0” indicates two examples) and after 24 hours treatment with VEGF-DΔNΔC, VEGF-CΔNΔC or the 
3Ala variant of each (“D3Ala” and “C3Ala”, respectively).  “No GF” denotes two results after 24 hours 
with no growth factor.  White lines indicate edges of the wounds.  In A and B, the capacity of variants to 
activate VEGFR-2 (R2) or VEGFR-3 (R3) is indicated above the graphs, and asterisks indicate that 
results differ from “No GF” in a statistically significant fashion, as assessed by one-way analysis of 
variance with Tukey’s Post-Hoc Test.  The amounts of VEGF-D or VEGF-C variants were matched in 
each assay. 
 
 
FIGURE 6.  Assessment of the D103A variant and VEGF-DΔNΔC for receptor interactions, 
stimulation of COX-2 expression and sprouting lymphangiogenesis.  A. Bioassays for binding and 
cross-linking of extracellular domains of VEGFR-2 (left) and VEGFR-3 (right) with VEGF-DΔNΔC 
(“VEGF-D”) and the D103A variant of VEGF-DΔNΔC.  Data points denote mean and error bars indicate 
standard deviation.  B. Effect of VEGF-DΔNΔC, the D103A variant and other selected variants of VEGF-
DΔNΔC (grey bars), and VEGF-CΔNΔC (“VEGF-C”) and the 3Ala variant of VEGF-C (“C3Ala”) (black 
bars) on level of COX-2 mRNA in adult LECs as assessed by quantitative RT-PCR (“D3Ala” denotes the 
3Ala variant of VEGF-DΔNΔC).  Cells were exposed to 100 ng/ml of ligands for 30 min prior to lysis for 
RNA preparation, as described in Experimental Procedures.  COX-2 mRNA levels were normalized to -
actin and are expressed relative to the level in cells that were not treated with ligand (“No GF”).  Columns 
show mean and error bars denote standard deviation.  C. Titrations of VEGF-DΔNΔC and VEGF-
CΔNΔC in the VEGFR-3 bioassay (left) and for the capacity to increase COX-2 mRNA levels in LECs 
(right).  Fold increases of COX-2 mRNA are relative to cells that were not treated with growth factor.  In 
both graphs, data points indicate the mean and error bars denote standard deviation.  D. VEGF-DΔNΔC 
and the D103A variant (1 g) were subcutaneously injected into ears of mice every 24 h for 3 days as 
described in Experimental Procedures; PBS was negative control.  Ears were harvested and stained for 
lymphatics using antibody to LYVE-1 (green) – the vessels shown are predominantly initial lymphatics.  
A high-power image of the region within the white rectangle in the D103A image, showing three 
lymphatic sprouts, is below the lower-power D103A image.  Red arrows indicate lymphatic sprouts, 
which are quantitated in the left-side graph; scale-bars indicate 50 m.  HPF denotes high-powered-field.  
The width of LYVE-1-positive lymphatics is quantified in the right-side graph.  In both graphs, columns 
show mean and error bars denote standard error of the mean.  In B and D, asterisks indicate statistically 
significant differences as assessed by one-way analysis of variance with Tukey’s Post-Hoc Test.   
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Supplementary Figure 1.  Analysis of purified variants of VEGF-DNC and VEGF-CNC used 
in this study by SDS-PAGE and Coomassie staining.  Proteins (approximately 1 g) were subjected to 
SDS-PAGE under reducing conditions and stained with Coomassie Brilliant Blue.  The expected sizes of 
the subunits of VEGF-DNC and VEGF-CNC variants are ~22 and ~24 kDa, respectively.  The 
multiple bands detected in the 18 to 24 kDa range for variants of VEGF-CNC are likely due to variable 
degrees of glycosylation.  Dotted lines indicate where irrelevant tracks have been removed from the 
images.  Molecular weight markers in kDa are shown to the right of the images. 
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